De-risk cross-border launches. Oak LS assesses whether your products—or whole portfolios—can enter Canada from Europe/Asia/Australia, and builds export strategies for Canadian brands expanding to the U.S., EU/UK, APAC, and beyond.
DIN drug, NHP, medical device, cosmetic, food, or VHP—and the right filing (e.g., CTA/NDS/SNDS, NHP licensing, MDL/MDEL, Cosmetic Notification, CFIA pathways for foods).
What label/advertising claims are supportable in Canada; literature bridging vs. new data; when “proportionate” studies make sense.
Required Canadian licences (e.g., DEL, NHP Site Licence, MDEL), GMP/GDP/GPP readiness, and importer models.
Plain-language, bilingual (EN/FR) labels, Drug Facts/NHP facts, outer/inner pack, HC-specific warnings.
Adverse event capture and periodic reporting expectations for self-care vs. drug products.
Service-standard estimates, critical path, budget bands, and risk mitigations.
Red flags (e.g., restricted ingredients, scheduling, LASA/brand conflicts) that drive a re-plan.
U.S. (FDA), EU/UK (EMA/MHRA), Australia (TGA), etc.—and where reliance/abridgement is realistic.
MDSAP, EU MDR/IVDR, 510(k)/De Novo, UKCA—gap mapping from Canadian files and QMS.
What Canadian-approved claims can carry over; what must be toned down or re-evidenced.
Drug Facts vs. SmPC/PL, local language mandates, container/closure norms.
Pharmacy vs. mass market, pharmacist-only schedules, importer of record, local RP/EC requirements.
Name conflicts/LASA and trade-dress considerations in destination markets.
Outcome: a clear, defensible decision on market entry—plus a step-by-step plan to license, label, and launch with fewer surprises.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.